Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response

Abstract

Imaging plays a notable role in hepatocellular carcinoma (HCC) surveillance, diagnosis, and treatment response assessment. Whereas HCC surveillance among at-risk patients, including those with cirrhosis, has traditionally been ultrasound-based, there are increasing data showing that this strategy is operator-dependent and has insufficient sensitivity when used alone. Several novel blood-based and imaging modalities are currently being evaluated to increase sensitivity for early HCC detection. Multi-phase computed tomography (CT) or contrast-enhanced magnetic resonance imaging (MRI) should be performed in patients with positive surveillance tests to confirm a diagnosis of HCC and perform cancer staging, as needed. HCC is a unique cancer in that most cases can be diagnosed radiographically without histological confirmation when demonstrating characteristic features such as arterial phase hyperenhancement and delayed phase washout. The Liver Imaging Reporting and Data System offers a standardized nomenclature for reporting CT or MRI liver findings among at-risk patients. Finally, cross-sectional imaging plays a critical role for assessing response to any HCC therapy as well as monitoring for HCC recurrence in those who achieve complete response.

Keywords

Liver cancer / ultrasound / screening / computed tomography / magnetic resonance imaging / contrast-enhanced ultrasound / Liver Imaging Reporting and Data System

References

[1] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries..CA Cancer J Clin2018;68:394-424

[2] Marrero JA,Sirlin CB,Finn RS.Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases..Hepatology2018;68:723-50

[3] European Association for the Study of the Liver. European association for the study of the liverEASL Clinical practice guidelines: management of hepatocellular carcinoma..J Hepatol2018;69:182-236

[4] Zhang BH,Tang ZY.Randomized controlled trial of screening for hepatocellular carcinoma..J Cancer Res Clin Oncol2004;130:417-22

[5] Singal AG,Tiro J.Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis..PLoS Med2014;11:e1001624 PMCID:PMC3972088

[6] Omata M,Kokudo N,Lee JM.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update..Hepatol Int2017;11:317-70 PMCID:PMC5491694

[7] Kokudo N,Hasegawa K,Kubo S.Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update..Hepatol Res2019;49:1109-13

[8] Tzartzeva K,Rich NE,Marrero JA.Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis..Gastroenterology2018;154:1706-18.e1 PMCID:PMC5927818

[9] Jeong WK.Surveillance of hepatocellular carcinoma: is only ultrasound enough?.Clin Mol Hepatol2017;23:222-3 PMCID:PMC5628009

[10] Lee CI,Elmore JG.Risk-based breast cancer screening: implications of breast density..Med Clin North Am2017;101:725-41 PMCID:PMC5458625

[11] Berg WA,Cormack JB.Operator dependence of physician-performed whole-breast US: lesion detection and characterization..Radiology2006;241:355-65

[12] Madjar H,Jellins J.IBUS guidelines for the ultrasonic examination of the breast..Eur J Ultrasound1999;9:99-102

[13] Choi EJ,Kim YM,Lee JH.Interobserver agreement in breast ultrasound categorization in the Mammography and Ultrasonography Study for Breast Cancer Screening Effectiveness (MUST-BE) trial: results of a preliminary study..Ultrasonography2019;38:172-80 PMCID:PMC6443585

[14] Finberg HJ.Whither (wither?) the ultrasound specialist?.J Ultrasound Med2004;23:1543-7

[15] Simmons O,Yokoo T,Yopp A.Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis..Aliment Pharmacol Ther2017;45:169-77 PMCID:PMC7207219

[16] Mellinger JL,Winder GS,Adams M.The high burden of alcoholic cirrhosis in privately insured persons in the United States..Hepatology2018;68:872-82

[17] Perumpail BJ,Yoo ER,Kim D.Clinical epidemiology and disease burden of nonalcoholic fatty liver disease..World J Gastroenterol2017;23:8263-76 PMCID:PMC5743497

[18] Schoenberger H,Yokoo T,Singal AG.Correlates of ultrasound quality for HCC surveillance in patients with cirrhosis..Gastroenterology2020;158:S-91

[19] Santagostino E,Rivi M,Rocino A.A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus..Blood2003;102:78-82

[20] Rich NE,Parikh ND,Mehta N.Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multi-center cohort of patients with cirrhosis..Hepatology2020; PMCID:PMC7398837

[21] Santi V,Gramenzi A,Mirici-Cappa F.Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival..J Hepatol2010;53:291-7

[22] Trinchet JC,Bourcier V,Henrion J.Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities..Hepatology2011;54:1987-97

[23] Rich N.Hepatocellular carcinoma tumour markers: current role and expectations..Best Pract Res Clin Gastroenterol2014;28:843-53

[24] Gopal P,Waljee AK,Nehra M.Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis..Clin Gastroenterol Hepatol2014;12:870-7 PMCID:PMC3975698

[25] Yang JD,Singal AG,Addissie BD.Improved performance of serum alpha-fetoprotein for hepatocellular carcinoma diagnosis in HCV cirrhosis with normal alanine transaminase..Cancer Epidemiol Biomarkers Prev2017;26:1085-92 PMCID:PMC5519351

[26] Minami T,Kondo M,Fujiwara N.Serum alpha-fetoprotein has high specificity for the early detection of hepatocellular carcinoma after hepatitis C virus eradication in patients..Medicine (Baltimore)2015;94:e901 PMCID:PMC4616483

[27] Wong GL,Tse YK,Tse CH.On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir..Hepatology2014;59:986-95

[28] Atiq O,Yopp AC,Marrero JA.An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis..Hepatology2017;65:1196-205 PMCID:PMC5659110

[29] Berhane S,Tada T,Kagebayashi C.Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients..Clin Gastroenterol Hepatol2016;14:875-86.e6

[30] Best J,Sowa JP,Dechêne A.GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis..Clin Gastroenterol Hepatol2020;18:728-35.e4

[31] Yang JD,Mara KC,Dai J.GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score..Cancer Epidemiol Biomarkers Prev2019;28:531-8 PMCID:PMC6401221

[32] Ye Q,Zheng S.Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA..Mol Cancer2019;18:114 PMCID:PMC6607541

[33] Ahn JC,Chen PJ,Tseng HR.Detection of circulating tumor cells and their implications as a novel biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma..Hepatology2020;

[34] Chalasani NP, Ramasubramanian T, Bruinsma JJ, et al. Combined methlylated DNA and protein markers: An accurate blood-based test for early stage detection of hepatocellular carcinoma, In American Association for the Study of Liver Diseases: Hepatology 2019; 70(S1): 72A-73A. Available from https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.30940 [Last accessed on 26 Aug 2020]

[35] Pocha C,McMaken KA,Thuras P.Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography -- a randomised study..Aliment Pharmacol Ther2013;38:303-12

[36] Harris PS,Gray ME,McGuire BM.Hepatocellular carcinoma surveillance: an evidence-based approach..World J Gastroenterol2019;25:1550-9 PMCID:PMC6452232

[37] Andersson KL,Goldie SJ.Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis..Clin Gastroenterol Hepatol2008;6:1418-24 PMCID:PMC4340842

[38] Kim SY,Lim YS,Lee JY.MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma..JAMA Oncol2017;3:456-63 PMCID:PMC5470420

[39] Kim HL,Park JA,Lim YS.Magnetic resonance imaging is cost-effective for hepatocellular carcinoma surveillance in high-risk patients with cirrhosis..Hepatology2019;69:1599-613

[40] Lee JY,Weinstein S,Monto A.Evaluation of an abbreviated screening MRI protocol for patients at risk for hepatocellular carcinoma..Abdom Radiol (NY)2018;43:1627-33

[41] Khatri G,Ananthakrishnan L,Fetzer DT.Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: An equivalence study using LI-RADS v2018..J Magn Reson Imaging2020;51:415-25

[42] Park HJ,Kim SY,Won HJ.Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: comparison with ultrasound..J Hepatol2020;72:718-24

[43] An C,Choi JY,Roh YH.Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance (MIRACLE-HCC): study protocol for a prospective randomized trial..BMC Cancer2018;18:915 PMCID:PMC6154402

[44] Kim HA,Choi JI,Lee CH.Comparison of biannual ultrasonography and annual non-contrast liver magnetic resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol..BMC Cancer2017;17:877 PMCID:PMC5740703

[45] Hoshida Y,Sangiovanni A,Hur C.Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis..Gastroenterology2013;144:1024-30 PMCID:PMC3633736

[46] Ioannou GN,Kerr KF.Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification..J Hepatol2019;71:523-33 PMCID:PMC6702126

[47] Goossens N,Hoshida Y.Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated?.Curr Hepatol Rep2017;16:64-71 PMCID:PMC5358664

[48] Singal AG,S Skinner C,Lee WM.Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review..J Gen Intern Med2012;27:861-7 PMCID:PMC3378733

[49] Singal AG,Tiro J,Adams-Huet B.Racial, social, and clinical determinants of hepatocellular carcinoma surveillance..Am J Med2015;128:90.e1-7 PMCID:PMC4282818

[50] Farvardin S,Khambaty M,Mok H.Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis..Hepatology2017;65:875-84 PMCID:PMC5568252

[51] Simmons OL,Parikh ND.Primary care provider practice patterns and barriers to hepatocellular carcinoma surveillance..Clin Gastroenterol Hepatol2019;17:766-73 PMCID:PMC7212522

[52] Beste LA,Yang Y,Ross D.Improved surveillance for hepatocellular carcinoma with a primary care-oriented clinical reminder..Clin Gastroenterol Hepatol2015;13:172-9

[53] Singal AG,Murphy CC,McCallister K.Mailed outreach invitations significantly improve HCC surveillance rates in patients with cirrhosis: a randomized clinical trial..Hepatology2019;69:121-30 PMCID:PMC6324997

[54] Singal AG,Marrero JA,Mejias C.Mailed outreach program increases ultrasound screening of patients with cirrhosis for hepatocellular carcinoma..Gastroenterology2017;152:608-15.e4 PMCID:PMC5285373

[55] Fetzer DT,Harris AC,Wasnik AP.Screening and surveillance of hepatocellular carcinoma: an introduction to ultrasound liver imaging reporting and data system..Radiol Clin North Am2017;55:1197-209

[56] Marrero JA,Nghiem HV,Fontana RJ.Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass..Liver Transpl2005;11:281-9

[57] Tang A,Corwin MT,Dietrich CF.Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review..Radiology2018;286:29-48 PMCID:PMC6677284

[58] Elsayes KM,Chernyak V,Furlan A.LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance..J Hepatocell Carcinoma2019;6:49-69 PMCID:PMC6368120

[59] van der Pol CB,Sirlin CB,Salameh JP.Accuracy of the liver imaging reporting and data system in computed tomography and magnetic resonance image analysis of hepatocellular carcinoma or overall malignancy-a systematic review..Gastroenterology2019;156:976-86

[60] Shao S,Kuang S,Shan Q.Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection..Bosn J Basic Med Sci2020;20:401-10 PMCID:PMC7416181

[61] Roberts LR,Zaiem F,Prokop LJ.Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis..Hepatology2018;67:401-21

[62] Lee YJ,Lee JS,Park BH.Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis..Radiology2015;275:97-109

[63] Kim JY,Kim KA,Park YN.Hyperintense HCC on hepatobiliary phase images of gadoxetic acid-enhanced MRI: correlation with clinical and pathological features..Eur J Radiol2012;81:3877-82

[64] Sirlin CB,Jonas E,Min Lee J.Consensus report from the 6th International forum for liver MRI using gadoxetic acid..J Magn Reson Imaging2014;40:516-29

[65] Lu RC,Gao WT,Xu DD.Positron-emission tomography for hepatocellular carcinoma: Current status and future prospects..World J Gastroenterol2019;25:4682-95 PMCID:PMC6718031

[66] Brix G,Bellemann ME,Schosser R.Quantification of [(18)F]FDG uptake in the normal liver using dynamic PET: impact and modeling of the dual hepatic blood supply..J Nucl Med2001;42:1265-73

[67] Wudel LJ Jr.,Morris D,Washington MK.The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma..Am Surg2003;69:117-24discussion 124-6

[68] Jadvar H.Hepatocellular carcinoma and gastroenteropancreatic neuroendocrine tumors: potential role of other positron emission tomography radiotracers..Semin Nucl Med2012;42:247-54

[69] Ehman EC,Villanueva-Meyer JE,Leynes AP.PET/MRI: Where might it replace PET/CT?.J Magn Reson Imaging2017;46:1247-62 PMCID:PMC5623147

[70] Hernandez R,England CG,Ehlerding EB.CD146-targeted immunoPET and NIRF imaging of hepatocellular carcinoma with a dual-labeled monoclonal antibody..Theranostics2016;6:1918-33 PMCID:PMC4997246

[71] Jo PC,Burns PN,Kim TK.Integration of contrast-enhanced US into a multimodality approach to imaging of nodules in a cirrhotic liver: how I do it..Radiology2017;282:317-31

[72] Kim TK,Wilson SR,Piscaglia F.Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 - a review of important differences compared to the CT/MRI system..Clin Mol Hepatol2017;23:280-9 PMCID:PMC5760002

[73] Zhang J,Li Y.Diagnostic value of contrast-enhanced ultrasound in hepatocellular carcinoma: a meta-analysis with evidence from 1998 to 2016..Oncotarget2017;8:75418-26 PMCID:PMC5650432

[74] Bartolotta TV,Midiri M.Contrast-enhanced ultrasound of hepatocellular carcinoma: where do we stand?.Ultrasonography2019;38:200-14 PMCID:PMC6595127

[75] Aubé C,Lonjon J,Seror O.EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice..Liver Int2017;37:1515-25

[76] Vilana R,Bianchi L,Rimola J.Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound..Hepatology2010;51:2020-9

[77] Chen LD,Xie XY,Xu ZF.Intrahepatic cholangiocarcinoma and hepatocellular carcinoma: differential diagnosis with contrast-enhanced ultrasound..Eur Radiol2010;20:743-53

[78] Wildner D,Goertz RS,Sturm J.Dynamic contrast-enhanced ultrasound (DCE-US) for the characterization of hepatocellular carcinoma and cholangiocellular carcinoma..Ultraschall Med2014;35:522-7

[79] Chen LD,Liang JY,Shen SL.Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma in high-risk patients: a predictive model using contrast-enhanced ultrasound..World J Gastroenterol2018;24:3786-98 PMCID:PMC6127655

[80] Shiina S,Obi S,Tateishi R.A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma..Gastroenterology2005;129:122-30

[81] Liu D,Chan AC,Khong PL.Hepatocellular carcinoma: surveillance CT schedule after hepatectomy based on risk stratification..Radiology2015;274:133-40

[82] Pavel MC.Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions..World J Gastroenterol2018;24:3626-36 PMCID:PMC6113720

[83] Yao FY,Flemming J,Hameed B.Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria..Hepatology2015;61:1968-77 PMCID:PMC4809192

[84] Yao FY,Bass NM,Ascher NL.Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging..Am J Transplant2007;7:2587-96

[85] Kardashian A,Haydel B,Klintmalm GB.Liver transplantation outcomes in a U.S. multicenter cohort of 789 patients with hepatocellular carcinoma presenting beyond milan criteria..Hepatology2020;

[86] Mehta N,Harnois DM,Dodge JL.Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant..JAMA Oncol2017;3:493-500 PMCID:PMC5395317

[87] Eisenhauer EA,Bogaerts J,Sargent D.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)..Eur J Cancer2009;45:228-47

[88] Bruix J,Llovet JM,Lencioni R.Clinical management of hepatocellular carcinoma. conclusions of the barcelona-2000 EASL conference..J Hepatol2001;35:421-30

[89] Lencioni R.Modified RECIST (mRECIST) assessment for hepatocellular carcinoma..Semin Liver Dis2010;30:52-60

[90] Gillmore R,Kirkwood A,Woodward N.EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization..J Hepatol2011;55:1309-16

[91] Fournier L,Thiam R.Imaging criteria for assessing tumour response: RECIST, mRECIST, Cheson..Diagn Interv Imaging2014;95:689-703

[92] Llovet JM,Mazzaferro V,Gane E.Sorafenib in advanced hepatocellular carcinoma..N Engl J Med2008;359:378-90

[93] Cheng A,Chen Z,Qin S.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial..Lancet Oncol2009;10:25-34

[94] Abou-Alfa GK,Cheng AL,Rimassa L.Cabozantinib in patients with advanced and progressing hepatocellular carcinoma..N Engl J Med2018;379:54-63

[95] Bruix J,Merle P,Huang Y.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial..Lancet2017;389:56-66

[96] Kudo M,Qin S,Ikeda K.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial..Lancet2018;391:1163-73

[97] Edeline J,Rolland Y,Pracht M.Comparison of tumor response by response evaluation criteria in solid tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma..Cancer2012;118:147-56

[98] Kudo M,Qin S,Ikeda K.Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT)..JCO2019;37:186

[99] Llovet JM,Villanueva A.Randomized trials and endpoints in advanced HCC: role of PFS as a surrogate of survival..J Hepatol2019;70:1262-77

[100] Bangaru S,Singal AG.Review article: new therapeutic interventions for advanced hepatocellular carcinoma..Aliment Pharmacol Ther2020;51:78-89

[101] El-khoueiry AB,Yau TC,Kudo M.Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040..JCO2018;36:475

[102] Grierson P,Ruzinova MB,Lim KH.Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: a case report of late response after pseudoprogression..Hepatol Commun2018;2:148-51 PMCID:PMC5796320

[103] Wong DJ,Choo SP,Hennedige T.Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series..Immunotherapy2019;11:167-75

[104] Seymour L,Perrone A,Schwartz LH.iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics..Lancet Oncol2017;18:e143-52 PMCID:PMC5648544

[105] Henze J,Persigehl T.RECIST 1.1, irRECIST 1.1, and mRECIST: how to do..Curr Radiol Rep2016;4:

[106] Edeline J,Zhu AX,Cattan S.RECIST v1.1 and irRECIST outcomes in advanced HCC treated with pembrolizumab (pembro)..JCO2020;38:528

[107] Zwanenburg A,Abdalah MA,Andrearczyk V.The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping..Radiology2020;295:328-38 PMCID:PMC7193906

[108] Kim Y,Borhani AA.Computer-aided diagnosis program for classifying the risk of hepatocellular carcinoma on MR images following liver imaging reporting and data system (LI-RADS)..J Magn Reson Imaging2018;47:710-22

[109] Hectors SJ,Besa C,Said D.MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma..Eur Radiol2020;30:3759-69